SMAD3 and idiopathic pulmonary fibrosis: Our present study showed PFD, a widely used anti‐fibrotic agent for IPF, alleviated cardiac fibrosis induced by pressure overload via inhibiting the TGF‐β1/Smad3 signalling pathway (Figure 5).